Founded in 2024, Analona Therapeutics is a biotech company located in Denmark focused on developing innovative antibody-based therapies for pancreatic cancer.
The company is built on cutting-edge research from the research group of Professor Axel Behrens at the Institute of Cancer Research in the UK, which has identified a range of novel targets and mechanisms of action.
Analona Therapeutics aims to discover and develop antibody based therapeutics against these targets with an initial focus on a key interactor and facilitator of metabolite transporters.
The company was recently accepted into the Venture Lab program of the BioInnovation Institute in Copenhagen.
Subscribe for alerts on new companies featured on Startups.Bio
Archon Biosciences
Archon Biosciences is a biotech company pioneering computationally designed 'Antibody Cages' to unlock powerful therapeutic targets beyond the reach of existing modalities. Archon directly applies generative protein design to rapidly …
Cytospire Therapeutics
Founded in 2023, Cytospire Therapeutics is developing a portfolio of next-generation immune cell engagers for treating cancer. The company's multispecific antibodies are designed to harness and direct the power of …
This Week in Biotech Venture Capital
The biotech sector continues to see a strong flow of new venture capital deals, with a flurry of new announcements this week. We saw a diverse set of companies—ranging from …
THRONCAT
THRONCAT is a new startup that aims to transform the field of protein analysis and mRNA therapeutics safety. THRONCAT began with a mission to make protein analysis more accessible and …
View all recently featured startups